These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 26860246)

  • 21. Science versus politics: the need for supervised injection facilities in Montreal, Canada.
    Jozaghi E
    Int J Drug Policy; 2012 Sep; 23(5):420-1. PubMed ID: 22818890
    [No Abstract]   [Full Text] [Related]  

  • 22. Prospects for scaling-up supervised injection facilities in Canada: the role of evidence in legal and political decision-making.
    Hyshka E; Bubela T; Wild TC
    Addiction; 2013 Mar; 108(3):468-76. PubMed ID: 23286831
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Supervised consumption rooms: the French Paradox.
    Jauffret-Roustide M; Pedrono G; Beltzer N
    Int J Drug Policy; 2013 Nov; 24(6):628-30. PubMed ID: 23777651
    [No Abstract]   [Full Text] [Related]  

  • 24. Commentary on Fraser et al. (2018): Evidence base for harm reduction services-the urban-rural divide.
    Lancaster KE; Malvestutto CD; Miller WC; Go VF
    Addiction; 2018 Jan; 113(1):183-184. PubMed ID: 29226535
    [TBL] [Abstract][Full Text] [Related]  

  • 25. How many HIV infections are prevented by Vancouver Canada's supervised injection facility?
    Pinkerton SD
    Int J Drug Policy; 2011 May; 22(3):179-83. PubMed ID: 21450450
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Commentary on Vickerman et al. (2012): Reducing hepatitis C virus among injection drug users through harm reduction programs.
    Smith-Spangler CM; Asch SM
    Addiction; 2012 Nov; 107(11):1996-7. PubMed ID: 23039752
    [No Abstract]   [Full Text] [Related]  

  • 27. Evaluating Vancouver's supervised injection facility: data and dollars, symbols and ethics.
    Des Jarlais DC; Arasteh K; Hagan H
    CMAJ; 2008 Nov; 179(11):1105-6. PubMed ID: 19015552
    [No Abstract]   [Full Text] [Related]  

  • 28. Do needle syringe programs reduce HIV infection among injecting drug users: a comprehensive review of the international evidence.
    Wodak A; Cooney A
    Subst Use Misuse; 2006; 41(6-7):777-813. PubMed ID: 16809167
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Services for drug users. Making a difference in many lives].
    Medellín JM
    Sidahora; 2005; ():12-7. PubMed ID: 16634157
    [No Abstract]   [Full Text] [Related]  

  • 30. The Latin American harm reduction network (RELARD): successes and challenges.
    Bueno R
    Int J Drug Policy; 2007 Mar; 18(2):145-7. PubMed ID: 17689358
    [No Abstract]   [Full Text] [Related]  

  • 31. French People's positions on supervised injection facilities for drug users.
    Munoz Sastre MT; Kpanake L; Mullet E
    Subst Abuse Treat Prev Policy; 2020 Oct; 15(1):79. PubMed ID: 33054832
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safer injecting facilities-is the research there? A comment on Caulkins et al. (2019).
    Belackova V; Salmon AM; Jauncey M; Day CA
    Addiction; 2020 Apr; 115(4):784-785. PubMed ID: 31692143
    [No Abstract]   [Full Text] [Related]  

  • 33. The willingness of people who inject drugs in Boston to use a supervised injection facility.
    León C; Cardoso L; Mackin S; Bock B; Gaeta JM
    Subst Abus; 2018 Jan; 39(1):95-101. PubMed ID: 28799847
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Peer counseling perspectives. Harm reduction all around.
    Hemphill ML
    Surviv News (Atlanta Ga); 2005; 16(6):7. PubMed ID: 16388537
    [No Abstract]   [Full Text] [Related]  

  • 35. The ever-changing narrative: Supervised injection site policy making in Ontario, Canada.
    Ziegler BR; Wray AJ; Luginaah I
    Int J Drug Policy; 2019 Dec; 74():98-111. PubMed ID: 31586776
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Willingness to use a supervised injection facility among young adults who use prescription opioids non-medically: a cross-sectional study.
    Bouvier BA; Elston B; Hadland SE; Green TC; Marshall BD
    Harm Reduct J; 2017 Feb; 14(1):13. PubMed ID: 28219388
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emerging role of supervised injecting facilities in human immunodeficiency virus prevention.
    Milloy MJ; Wood E
    Addiction; 2009 Apr; 104(4):620-1. PubMed ID: 19335659
    [No Abstract]   [Full Text] [Related]  

  • 38. [ESAP. More access to syringes].
    Caceres W
    Sidahora; 2005; ():18-21. PubMed ID: 16634158
    [No Abstract]   [Full Text] [Related]  

  • 39. New data confirm lack of progress in harm reduction after three decades of proven evidence of effectiveness.
    Macdonald V; Mathers B; Sabin K; Me A; Carpentier C; Niaz K; Mozalevskis A; Luhmann N; Ciupagea M; Soltani F; Verster A
    Addiction; 2023 Aug; 118(8):1411-1413. PubMed ID: 37051682
    [No Abstract]   [Full Text] [Related]  

  • 40. The epidemiological impact and cost-effectiveness of HIV testing, antiretroviral treatment and harm reduction programs.
    Li J; Gilmour S; Zhang H; Koyanagi A; Shibuya K
    AIDS; 2012 Oct; 26(16):2069-78. PubMed ID: 22781221
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.